Xcout IntelJupiter Neurosciences, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Jupiter Neurosciences, Inc. among pharmaceuticals companies — ranked by similarity to what Jupiter Neurosciences, Inc. actually does, not by market-cap band.
Subscribe to see Jupiter Neurosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Jupiter Neurosciences, Inc. at a glance
Jupiter Neurosciences, Inc. is a pharmaceuticals company headquartered in Jupiter, United States. It is publicly listed (JUNS) with a market capitalisation of $3.7M. Xcout tracks 24 named people at Jupiter Neurosciences, Inc., including Alison D. Silva (President, COO & Director).
Jupiter Neurosciences, Inc. leadership
- Alison D. SilvaPresident, COO & Director
- Saleem ElmasriChief Financial Officer & Secretary
- Christer RosenCo-Founder, Chief Executive Officer & Chairman of the Board
- Alexander RosenCo-Founder & Chief Administrative Officer
- Marshall HaywardCo-Founder, Chief Scientific Officer & Director
- Claes WahlestedtCo-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
18 more named people on record for Jupiter Neurosciences, Inc., with roles, board committees and tenure — see the full roster →
Jupiter Neurosciences, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $7.5M | 2 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Jupiter Neurosciences, Inc. competitors
Ranked by semantic similarity — how close each company is to Jupiter Neurosciences, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
J2 Bio-Pharma, LLC is a specialty pharmaceutical company that reformulates neurology medications to address unmet medical needs. The company partners with pharmacies, patients, and businesses in the healthcare sector to develop and commercialize therapeutic products.
Pharmaceuticals, Biotechnology & Life Sciences
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Similar pharmaceuticals company
THX Pharma is a biopharmaceutical company that develops therapeutic solutions for rare neurological diseases such as Batten disease, Niemann-Pick type C, and Gaucher disease. The company utilizes antisense oligonucleotides and scientific research to create targeted drug candidates for patients with limited treatment options.
Similar pharmaceuticals company
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
Pharmaceuticals, Biotechnology & Life Sciences
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Similar pharmaceuticals company
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Similar pharmaceuticals company
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Similar pharmaceuticals company
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Similar pharmaceuticals company
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Similar pharmaceuticals company
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Similar pharmaceuticals company
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Similar pharmaceuticals company
Reata Pharmaceuticals was a U.S. biopharmaceutical company that developed therapies for serious and rare diseases, including neurological and metabolic disorders. Its drug Skyclarys (omaveloxolone) was approved for Friedreich’s ataxia before Reata was acquired by Biogen in 2023.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Jupiter Neurosciences, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Jupiter Neurosciences, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →